Targeting obesity, metabolic syndrome, and prostate cancer: GLP-1 agonists as emerging therapeutic agents DOI Creative Commons

Azura Murphy,

Ritis Kumar Shyanti, Manoj Kumar Mishra

и другие.

Discover Oncology, Год журнала: 2025, Номер 16(1)

Опубликована: Март 1, 2025

Prostate cancer (PCa) is known as the second most common and has one of highest incidences among male cancers in United States. In addition, obesity metabolic syndrome are a rising continuous issue States, with 41.9% individuals obese. The importance highlighting these figures possibility PCa having progressive relationship syndromes. drugs developed for treating diabetes pose an exciting therapeutic application efforts to relieve population's numbers. Although this connection not been established detail, there some key biomarkers, their interactions products found obese, diabetic, patients can provide good starting points further investigation. One significant links between PCa, obesity, disease may be due insulin metabolism. A downstream target identified that could link syndromes, forkhead box C2 (FOXC2). FOXC2 inhibit insulin-resistant genes cause proliferation PCa. relationships FOXC2, resistance, GLP-1 receptor agonists potential applications have thoroughly explored. This review covers broad possible drugs, targets.

Язык: Английский

Patient-Derived Organoid Models for NKT Cell-Based Cancer Immunotherapy DOI Open Access
Pablo A. Palacios,

Iván Flores,

Lucas Cereceda

и другие.

Cancers, Год журнала: 2025, Номер 17(3), С. 406 - 406

Опубликована: Янв. 26, 2025

Invariant Natural Killer T (iNKT) cells are a unique subset of that bridge innate and adaptive immunity, displaying potent anti-tumor properties through cytokine secretion, direct cytotoxicity, recruitment immune effector such as CD8+ NK cells. Despite their therapeutic potential, the immunosuppressive tumor microenvironment (TME), characterized by regulatory cells, myeloid-derived suppressor (MDSCs), tumor-associated macrophages (TAMs), limits iNKT cell efficacy. Patient-derived organoid (PDO) platforms provide an innovative model for dissecting these complex interactions evaluating strategies to reinvigorate functionality within TME. PDOs closely mimic genetic, phenotypic, structural characteristics primary tumors, enabling study tumor–immune dynamics. Integrating into offers robust platform investigating CD1d-mediated interactions, Th1-biased responses driven glycolipid analogs like α-GalCer, combination therapies checkpoint inhibitors. Additionally, PDO systems can assess effects metabolic modulation, including reducing lactic acid accumulation or targeting glutamine pathways, on enhancing activity. Emerging innovations, organoid-on-a-chip systems, CRISPR-Cas9 gene editing, multi-omics approaches, further expand potential PDO–iNKT personalized immunotherapy research. Although application in is still undeveloped, hold immense promise bridging preclinical studies clinical translation. By addressing challenges TME optimizing strategies, offer transformative avenue advancing cancer medicine.

Язык: Английский

Процитировано

0
Targeting obesity, metabolic syndrome, and prostate cancer: GLP-1 agonists as emerging therapeutic agents DOI Creative Commons

Azura Murphy,

Ritis Kumar Shyanti, Manoj Kumar Mishra

и другие.

Discover Oncology, Год журнала: 2025, Номер 16(1)

Опубликована: Март 1, 2025

Prostate cancer (PCa) is known as the second most common and has one of highest incidences among male cancers in United States. In addition, obesity metabolic syndrome are a rising continuous issue States, with 41.9% individuals obese. The importance highlighting these figures possibility PCa having progressive relationship syndromes. drugs developed for treating diabetes pose an exciting therapeutic application efforts to relieve population's numbers. Although this connection not been established detail, there some key biomarkers, their interactions products found obese, diabetic, patients can provide good starting points further investigation. One significant links between PCa, obesity, disease may be due insulin metabolism. A downstream target identified that could link syndromes, forkhead box C2 (FOXC2). FOXC2 inhibit insulin-resistant genes cause proliferation PCa. relationships FOXC2, resistance, GLP-1 receptor agonists potential applications have thoroughly explored. This review covers broad possible drugs, targets.

Язык: Английский

Процитировано

0